Statement on the use of Dexamethasone for severely ill COVID-19 Patients

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email
Share on print

This statement aims to provide guidance and recommendation to African Union Member States.

Africa Centers for Disease Control and Prevention (Africa CDC) is aware of the media releases of the preliminary results of a large randomized clinical trial conducted in the United Kingdom, which included dexamethasone, a corticosteroid, as one of the drugs used for the treatment of COVID-19 patients. The investigators reported that administration of oral or injectable dexamethasone resulted in about one-third reduction in mortality among COVID-19 patientsi that required mechanical ventilation and about one-fifth for patients requiring oxygen.

Download Files
Statement on the Use of Dexamethasone for Severely Ill COVID-19 PatientsDownload 

Scroll to Top